Ophthalmology

Increases in the working-age population during the 30-year period may have contributed to the global burden of visual impairment

These new findings represent the only PTC case to look at such a unique number of concurrent comorbidities in current medical literature.

These phase 2 data indicate that the implant may be a helpful addition to clinicians’ interventional glaucoma armamentarium for patients.

Significant increases in macular and choroidal thickness were observed in the fovea and perifovea at all postoperative visits in patients with diabetic retinopathy.

Results from a systematic review highlighted the clinical need for specific biomarkers for PAD and the viability of noninvasive ophthalmic imaging techniques for diagnosis.

A substudy of the ASCEND trial offers insight into the effects of omega-3 fatty acids use on risk of diabetic retinopathy in people with diabetes.

In a new study, inserting the XEN-45 implant in patients with uncontrolled uveititc glaucoma prevented conventional glaucoma surgery in 83.3% of patients.

Investigators observed differences in choroidal and inner neural layers among patients previously infected with COVID-19 compared to healthy controls.

A systematic review and meta-analysis provides insight into the potential for increased risk of noninfectious uveitis among people with vitamin D deficiency.

Gene therapy with mRNA is more cost-efficient, has a better safety profile, and is more reproducible than the viral vector, AAV, currently used for gene therapy to improve inherited retinal diseases.

The review emphasized the importance of therapies that provide sustained visual outcomes, given the increasing incidence of nAMD among aging adults.

Real-world data shows extended intervals with both brolucizumab alone or alternating anti-VEGF treatment regimens after 12 and 18 months in nAMD eyes.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our November 2023 month-in-review features a trio of FDA news, important updates to the GA pipeline, and insight into disparities in eye care.

We kick off our annual recap series with some reflections from our expert advisory board, on topics ranging from AI and cell therapies, to semaglutide and RSV vaccines.

Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.

By 2040, the number of blindness and vision loss cases are estimated to increase by roughly 50% across Brazil, Russia, India, China, and South America, a new study found.

Of 1023 color fundus photograph images, the 5 optometrists in the study were able to accuracy diagnosis 226 images with AMD.

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

Standard-Field Fundus Camera performs well in detecting proliferative sickle cell retinopathy, but performs poorly detecting non-proliferative sickle cell retinopathy, a new study found.

After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.

Only the states California, Delaware, Nevada, New Jersey, Oregon, and Pennsylvania require physicians to report medically impaired drivers, and 66% of states reported there was instructions on reporting available on DMV websites.

Household primary language was associated with vision screening, with children from non-English households exhibiting lower rates of pediatric vision screening.

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

Sent on November 13, 2023, the FDA letter warns Amazon on the introduction of unapproved new eye drop products into interstate commerce on their website.

Presented at AAO 2023, Kendra Klein-Mascia, MD, discussed her team’s study, comparing faricimab with aflibercept. The study found 2 injections of faricimab gets rid of 75% of retina fluid by week 8, but for aflibercept, erasing the same amount of fluid takes 3 injections until week 12.

At the end of year 2, 80% of patients on faricimab reached > q12 week dosing, and 63% achieved q16 dosing.

Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

Presented at AAO 2023, a study analyzed which race was associated more with having a glaucoma-associated diagnosis, as well as races’ knowledge, attitude, and beliefs about eye care.

Eligibility criteria prevents more Black individuals than White individuals from participating in clinical trials for diabetic macular edema.

Durga S. Borkar, MD, MMCi, presented her study at AAO 2023 which found trial eligibility discriminates against race/ethnicity.